Why the study?
Valvular heart disease imposes a heavy burden in the aging global population amidst a booming era of transcatheter treatment, requiring a review of current devices, clinical evidence, and future challenges.
What is the current status and what are the challenges of transcatheter interventional therapy for valvular heart disease?
What is the current status and what are the challenges of transcatheter interventional therapy for valvular heart disease?
This review provides a comprehensive overview of the booming era of transcatheter therapies for valvular heart disease, summarizing current technologies and future challenges.
Valvular heart disease (VHD) is common in the global population, occupying an heavy disease burden among aging population. Currently, it is the booming era of transcatheter VHD treatment, even with superiority than traditional open heart surgery in some clinical outcomes. We collected data sources mainly derived from published articles and conference presentations, including randomized controlled trials, first-in-man studies, clinical registries, and other single- or multi-center and prospective or retrospective clinical studies. This review summarized the relevant devices and researches of transcatheter aortic valve replacement, transcatheter mitral valve repair and replacement, transcatheter tricuspid valve repair and replacement, and transcatheter pulmonary valve replacement. Moreover, possible challenges of interventional therapy for various VHD in the future were discussed as well.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: